Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opdivo Reimbursement Rejected In Scotland

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb's skin cancer therapy, Opdivo (nivolumab), has been rejected for use on the Scottish National Health System – an unusual decision considering the drug's recent approval for use in England and Wales.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register